{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:58:32Z","timestamp":1768885112630,"version":"3.49.0"},"reference-count":95,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,21]],"date-time":"2011-03-21T00:00:00Z","timestamp":1300665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Autoimmune hepatitis (AIH) is an immune\u2010mediated necroinflammatory condition of the liver. Presentation can vary from the asymptomatic individual with abnormal liver function test to fulminant liver failure. The diagnosis is based on the combination of biochemical, autoimmune, and histological parameters, and exclusion of other liver diseases. Standard therapy consists of a combination of corticosteroids and azathioprine, which is efficacious in 80% of patients. Alternative therapies are increasingly being explored in patients who do not respond to the standard treatment and\/or have unacceptable adverse effects. This review examines the role of alternative drugs (second\u2010line agents) available for AIH treatment non\u2010responders. These agents include budesonide, mycophenolate mofetil, cyclosporin, tacrolimus, 6\u2010mercaptopurine, 6\u2010thioguanine, rituximab, ursodeoxycholic acid, rapamycin, and methotrexate. In addition, the risk of opportunistic infections and malignancies are discussed. A treatment algorithm is proposed for the management of patients with AIH treatment non\u2010responders.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2010.06579.x","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T11:01:34Z","timestamp":1289818894000},"page":"619-627","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Treatment of autoimmune hepatitis: A review of current and evolving therapies"],"prefix":"10.1111","volume":"26","author":[{"given":"Dinesh","family":"Jothimani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew E","family":"Cramp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon D","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim J S","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"key":"e_1_2_16_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06384.x"},{"key":"e_1_2_16_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.5.713"},{"key":"e_1_2_16_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1998.tb00674.x"},{"key":"e_1_2_16_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/26.6.441"},{"key":"e_1_2_16_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840130415"},{"key":"e_1_2_16_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2007.00204.x"},{"key":"e_1_2_16_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21059"},{"key":"e_1_2_16_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb05996.x"},{"key":"e_1_2_16_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21796"},{"key":"e_1_2_16_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.08.010"},{"key":"e_1_2_16_12_2","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.1.2.329"},{"key":"e_1_2_16_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.259"},{"key":"e_1_2_16_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92024-1"},{"key":"e_1_2_16_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.053"},{"key":"e_1_2_16_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.04.009"},{"key":"e_1_2_16_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"e_1_2_16_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80453-9"},{"key":"e_1_2_16_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322"},{"key":"e_1_2_16_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22513"},{"key":"e_1_2_16_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.06.013"},{"key":"e_1_2_16_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34944"},{"key":"e_1_2_16_23_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30991"},{"key":"e_1_2_16_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep0768"},{"key":"e_1_2_16_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20732"},{"key":"e_1_2_16_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.qjmed.a067264"},{"key":"e_1_2_16_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23584"},{"key":"e_1_2_16_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(73)92125-9"},{"key":"e_1_2_16_29_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.5694\/j.1326-5377.1957.tb59755.x","article-title":"The treatment of active chronic infectious hepatitis with ACTH (corticotrophin) and cortisone","volume":"44","author":"Last PM","year":"1957","journal-title":"Med. J. Aust."},{"key":"e_1_2_16_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.01.009"},{"key":"e_1_2_16_31_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6.177"},{"key":"e_1_2_16_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200105000-00014"},{"key":"e_1_2_16_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01153.x"},{"key":"e_1_2_16_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.02981.x"},{"key":"e_1_2_16_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000177260.72692.e8"},{"key":"e_1_2_16_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100008"},{"key":"e_1_2_16_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb35897.x"},{"key":"e_1_2_16_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000232331.93052.dd"},{"key":"e_1_2_16_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91329-7"},{"key":"e_1_2_16_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.004"},{"key":"e_1_2_16_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.05.011"},{"key":"e_1_2_16_42_2","first-page":"217","article-title":"Current status of autoimmune hepatitis in Japan","volume":"62","author":"Miyake Y","year":"2008","journal-title":"Acta Med. Okayama."},{"key":"e_1_2_16_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21787"},{"key":"e_1_2_16_44_2","first-page":"749","article-title":"Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan","volume":"11","author":"Hino T","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"e_1_2_16_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840030510"},{"key":"e_1_2_16_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30457.x"},{"key":"e_1_2_16_47_2","first-page":"341","article-title":"Mycophenolic acid formulations in adult renal transplantation\u2014update on efficacy and tolerability","volume":"5","author":"Golshayan D","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_2_16_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00188-0"},{"key":"e_1_2_16_49_2","first-page":"A1960","article-title":"Successful treatment of therapy\u2013refractory autoimmune hepatitis with mycophenolate mofetil","volume":"28","author":"Schuppan D","year":"1998","journal-title":"Hepatology."},{"key":"e_1_2_16_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80271-8"},{"key":"e_1_2_16_51_2","doi-asserted-by":"publisher","DOI":"10.1155\/2004\/504591"},{"key":"e_1_2_16_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2003.10.017"},{"key":"e_1_2_16_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01107.x"},{"key":"e_1_2_16_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.02.030"},{"key":"e_1_2_16_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.04.006"},{"key":"e_1_2_16_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02180.x"},{"key":"e_1_2_16_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-008-0632-0"},{"issue":"3","key":"e_1_2_16_58_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2036.1997.tb00814.x","article-title":"Review article: Drug development in inflammatory bowel disease: budesonide\u2014a model of targeted therapy","volume":"11","author":"Hamedani R","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_2_16_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00334.x"},{"key":"e_1_2_16_60_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/509459"},{"key":"e_1_2_16_61_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i9.1362"},{"key":"e_1_2_16_62_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.0010000001"},{"key":"e_1_2_16_63_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.046"},{"key":"e_1_2_16_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300603"},{"key":"e_1_2_16_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.06.013"},{"key":"e_1_2_16_66_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-916322"},{"key":"e_1_2_16_67_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010683817344"},{"key":"e_1_2_16_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.00807.x"},{"key":"e_1_2_16_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80065-8"},{"key":"e_1_2_16_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(07)60018-8"},{"key":"e_1_2_16_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80615-4"},{"key":"e_1_2_16_72_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i23.3232"},{"key":"e_1_2_16_73_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000139050.67178.be"},{"key":"e_1_2_16_74_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8536867"},{"key":"e_1_2_16_75_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200504000-00012"},{"key":"e_1_2_16_76_2","doi-asserted-by":"publisher","DOI":"10.1080\/00855920310002726"},{"key":"e_1_2_16_77_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01262.x"},{"key":"e_1_2_16_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3180f60b7a"},{"key":"e_1_2_16_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206939"},{"key":"e_1_2_16_80_2","unstructured":"BurakK Williamson\u2010CoffeyS SwainMet\u2003al.Rituximab for refractory autoimmune hepatitis: interim results of a phase 1 study.Canadian Digestive Disease Week.2009."},{"key":"e_1_2_16_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00801.x"},{"key":"e_1_2_16_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80128-1"},{"key":"e_1_2_16_83_2","first-page":"571","article-title":"Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis\u2014report of three cases","volume":"35","author":"Kanzler S","year":"1997","journal-title":"Z Gastroenterol."},{"key":"e_1_2_16_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.433"},{"key":"e_1_2_16_85_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.12.009"},{"key":"e_1_2_16_86_2","doi-asserted-by":"publisher","DOI":"10.1159\/000213364"},{"key":"e_1_2_16_87_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.012"},{"key":"e_1_2_16_88_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03973.x"},{"key":"e_1_2_16_89_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328326f3f8"},{"key":"e_1_2_16_90_2","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-004"},{"key":"e_1_2_16_91_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000173031.56429.04"},{"key":"e_1_2_16_92_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-008-9377-0"},{"key":"e_1_2_16_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2008.12.013"},{"key":"e_1_2_16_94_2","first-page":"407","article-title":"Swiss clinical practice guidelines for skin cancer in organ transplant recipients","volume":"139","author":"Hofbauer GF","year":"2009","journal-title":"Swiss Med. Wkly."},{"key":"e_1_2_16_95_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.578"},{"key":"e_1_2_16_96_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0128-5"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2010.06579.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2010.06579.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T21:03:06Z","timestamp":1697317386000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2010.06579.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1111\/j.1440-1746.2010.06579.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06579.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,21]]},"assertion":[{"value":"2011-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}